Your browser does not support JavaScript!

Home    Collections    Type of Work    Doctoral theses  

Doctoral theses

Search command : Author="Κοτζάμπασης"  And Author="Κυριάκος"

Current Record: 7 of 2410

Back to Results Previous page
Next page
Add to Basket
[Add to Basket]
Identifier 000460520
Title A prospective study of clinical and laboratory parameters in patients with non-small cell lung cancer undergoing immunotherapy : Correlation with clinical outcome
Alternative Title Μελέτη κλινικοεργαστηριακών παραμέτρων σε ασθενείς με μη μικροκυτταρικό καρκίνο πνεύμονος που υποβάλλονται σε ανοσοθεραπεία
Author Ρούνης, Κωνσταντίνος
Thesis advisor Μαυρουδής, Δημήτριος
Αγγελάκη, Σοφία
Reviewer Τζανάκης, Νικόλαος
Abstract Lung cancer constitutes the primary cause of mortality associated with malignancy on a global scale, with Non-Small Cell Lung Cancer (NSCLC) being its most prevalent histological subtype. Despite extensive research efforts spanning over three decades, the prognosis of patients with metastatic NSCLC remains poor. The introduction of immunotherapy into clinical practice has revolutionized oncology worldwide. Immunotherapy, delivered in the form of monoclonal antibodies targeting proteins that act as immune checkpoint inhibitors, offers the potential for prolonged remission in a small but significant subset of patients afflicted by a broad spectrum of neoplasms, including NSCLC. However, following the initial enthusiasm, a plethora of research inquiries emerged as a result of the necessity to enhance the clinical outcomes for our patients. A minority, approximately one-third, of patients receiving immunotherapy for NSCLC will derive clinical benefit from it. Additionally, the mechanisms of primary and acquired resistance to these monoclonal antibodies remain incompletely understood, and there exists a lack of predictive and prognostic biomarkers. Until now, only the levels of PD-L1 protein expression on the surface of cancer cells or immune cells within the tumor microenvironment have been statistically correlated with clinical outcomes in the prospective clinical trials which led to the regulatory approval of these drugs. Considering these aforementioned factors alongside the escalating cost of administering these medications, which places increasing economic strain on national healthcare systems, the identification of essential biomarkers becomes imperative. This is necessary not only for optimizing patient selection for immunotherapy in NSCLC, but also for decoding the mechanisms underlying primary and acquired resistance. A multitude of clinical, laboratory, and radiological parameters have been linked to the clinical outcome of patients with NSCLC undergoing cytotoxic chemotherapy. Furthermore, pharmaceutical agents such as antibiotics and steroids have been associated with diminished immune response and are frequently administered to patients with neoplasms undergoing immunotherapy. Moreover, factors associated with the pathogenesis of the cancer cachexia syndrome, diagnosed in approximately half of NSCLC patients, have been linked to reduced immune response and susceptibility to infections. Finally, the composition of adipose tissue in the human body has been indicated as a prognostic indicator in cancer patients and a significant regulator of the immune system, primarily in preclinical models. The objective of this doctoral dissertation was to conduct a prospective observational registry study on patients with NSCLC who received therapy at the Oncology Clinic of the University Hospital of Heraklion. The aim was to explore potential associations between clinical and laboratory factors, as well as the presence of cancer cachexia syndrome and adipose tissue composition, with the clinical outcome of these patients. During the two-year period from November 15, 2017, to November 15, 2019, prospective clinical, laboratory, and radiological data were collected for 83 patients with NSCLC who received immunotherapy at the University Hospital of Heraklion. The first publication resulting from this study analyzed the clinical and laboratory data of the 66 patients in our cohort who received immunotherapy as a second-line treatment. Prolonged administration of antibiotics (cumulatively for more than 14 days) and the presence of secondary osteopathic lesions emerged as independent negative predictive factors for disease stabilization after immunotherapy administration. Furthermore, these factors were also identified as independent prognostic factors for reduced survival. Interestingly, administration of antibiotics did not impact patient outcomes; only prolonged administration had a significant effect. The data were further analyzed using the JADBio artificial intelligence platform, which identified prolonged antibiotic administration, body mass index (BMI), and the presence of hepatic and bone metastases as significant factors associated with an increased likelihood of disease progression, indicating a less favorable response to immunotherapy. The resulting algorithm demonstrated an ability to predict disease stabilization probability at approximately 80%. These findings highlighted the pivotal role of the microbiome in orchestrating an effective immune response, as well as the adverse impact of the presence of osteopathic secondary lesions on the clinical outcome of metastatic NSCLC patients receiving immunotherapy. In the second scientific publication, the impact of cachexia syndrome presence on the clinical outcome of 83 patients with metastatic NSCLC receiving immunotherapy was investigated. Patient classification concerning the underlying cachexia syndrome was based on criteria previously established by the international consensus for this syndrome’s study in 2011. These criteria included weight loss exceeding 5% during the last six months before immunotherapy initiation, or any degree of weight loss > 2% and BMI < 20 kg/m2, or skeletal muscle mass index at the level of the third lumbar vertebra (LSMI) < 55 cm2/m2 for males and < 39 cm2/m2 for females. LSMI was calculated using computed tomography images of the abdomen at immunotherapy initiation and every 3 months thereafter, employing the Slice-O-Matic Tomovision method. Half of the cohort patients under study were diagnosed with cachexia syndrome. Cachectic patients exhibited statistically significantly lower response rates to immunotherapy compared to non-cachectic patients. Furthermore, the presence of cancer cachexia syndrome independently predicted an increased likelihood of disease progression as the optimal treatment response. Lastly, cachexia syndrome presence independently predicted reduced survival in patients with NSCLC receiving immunotherapy. This study, the first prospective investigation into the effect of cachexia syndrome on the clinical outcome of immunotherapy-treated patients, revealed that the presence of cancer cachexia syndrome constitutes an independent negative predictive and prognostic factor in patients with NSCLC undergoing immune checkpoint inhibitor therapy. Further research at translational and molecular levels concerning the metabolic dysregulation associated with cachexia syndrome presents a promising avenue for deciphering the mechanisms underlying both primary and secondary resistance to immunotherapy. In the third publication, prospective data from 52 patients in our cohort with sufficient or appropriate radiological data were analyzed. The objective of this study was to explore the impact of differential adipose tissue compartment composition and skeletal muscle tissue density on the therapeutic effectiveness of immunotherapy. Tissue composition was calculated by measuring the density of different types of adipose tissue (visceral, subcutaneous, and intramuscular fat) and muscle at the level of the third lumbar vertebra using computed tomography scans at immunotherapy initiation, applying the Slice-O-Matic Tomovision technique. Densities were converted into indices [Intramuscular Fat Index (IMFI), Visceral Fat Index (VFI), Subcutaneous Fat Index (SFI), Lumbar Skeletal Muscle Index (LSMI)] by dividing these values by the patients’ height squared. Patients were classified dichotomously based on their initial values of IMFI, VFI, and SFI, according to the median value for their gender. Muscle tissue classification was also dichotomous. The classification thresholds for LSMI were 55 cm2/m2 for males and 39 cm2/m2 for females, which were previously established by the international consensus for defining cachexia syndrome and serving as numerical thresholds for sarcopenia. Patients responding to immunotherapy had significantly higher SFI distributions compared to non-responders. The presence of sarcopenia and low subcutaneous fat density index were both significantly correlated with reduced survival in our cohort patients. An interesting finding was that in the univariate analysis exploring the correlation of IMFI, VFI, SFI, and LSMI as continuous variables with patient survival, the only variable that showed a statistically significant positive correlation was the subcutaneous fat density index. This study, the first prospective investigation into the effect of adipose tissue distribution on immunotherapy-treated NSCLC patients, highlighted the potential impact and significant role of subcutaneous adipose tissue density on immune response against malignancies at a clinical level. In conclusion, the scientific publications resulting from this doctoral thesis emphasized the significance of concomitant medications, particularly antibiotic treatment, as well as secondary bone lesions in the efficacy of immunotherapy in NSCLC patients. Moreover, the two publications investigating the influence of cachexia syndrome and adipose tissue distribution represent a “proof of concept” at a clinical level for the predictive and prognostic importance of metabolic dysregulation as a phenomenon occurring due to neoplastic processes in patients receiving immune response-modulating therapy. The study examining cachexia syndrome underscored the central role of advanced cachexia syndrome as a negative prognostic and predictive biomarker in the current era of immunotherapy. The results of the third study, revealing the predictive and significant role of subcutaneous fat density, represent clinical evidence of an additional and underexplored role. Further research at translational and molecular levels regarding the specific characteristics of the tumor microenvironment in cachectic patients as well as those with adipose tissue metabolic deregulation could serve as a pivotal link in the chain for discovering new biomarkers and therapies aiming to optimize immunotherapy as a cornerstone in cancer management.
Language English
Subject Adipose tissue
Antibiotics
Ανοσοθεραπεία
Λιπώδης ιστός
Issue date 2023-12-08
Collection   School/Department--School of Medicine--Department of Medicine--Doctoral theses
  Type of Work--Doctoral theses
Permanent Link https://elocus.lib.uoc.gr//dlib/d/5/6/metadata-dlib-1700729202-204013-31389.tkl Bookmark and Share
Views 804

Digital Documents
No preview available

Download document
View document
Views : 0